NCT01056770已完成3 期
An Open-label, Single Arm, Phase III Clinical Study to Evaluate the Efficacy and Safety of CJ Smallpox Vaccine in Vaccinia-naive Healthy Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 88
- 试验地点
- 1
- 主要终点
- Pocket formation
研究概览
简要总结
The currently available stock of smallpox vaccine would be insufficient in the face of an incident of smallpox attack. Thus, new manufacturing methods for smallpox vaccine are urgently needed because previous manufacturing methods using calf lymph are no longer acceptable in the view of current standards. Recently, CJ corporation in Republic of Korea has developed cell-culture derived smallpox vaccine (CJ-50300) which was manufactured by infecting MRC-5 cells. The aim of this clinical trial were to assess safety, reactogenicity, and immunogenicity of CJ-50300.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy Korean male and female subjects between 19 and 60 years of age at the time of screening visit
- •Willing to participate and have signed the informed consent form
- •In good general health, without clinically skin diseases history, physical examination or laboratory test results
- •Hematocrit > 33% for women; > 38% for men
- •White cell count 3,300-12,000/mm3
- •Total lymphocyte count > 800 cells/mm3
排除标准
- •Subjects who have been vaccinated with smallpox vaccines
- •Diseases or conditions that cause immunodeficiency (For examples; HIV AIDS, leukemia, lymphoma, generalized malignancy, agammaglobulinemia, history of transplantation, therapy with alkylating agents, antimetabolites, radiation, or oral or parenteral corticosteroids, basal cell carcinoma, liver cirrhosis or advanced liver disease).
- •In close physical contact (household or at work) with an individual who has the diseases or conditions that cause immunodeficiency
- •History or present of eczema or atopic dermatitis
- •Allergy or sensitivity to any known components of vaccine or other medicines
- •In close physical contact (household or at work) with an individual who has acute or chronic skin conditions such as dermatitis, exfoliative dermatitis
- •Subjects who have taken corticosteroid within 3 months of vaccination or who are taking oral or parenteral corticosteroid.
- •Subjects who have been taken immunosuppressive therapy including interferon within 3 months of vaccination or are taking immunosuppressive therapy.
- •Subjects who are planning for blood donations
- •Autoimmune disease such as lupus erythematosus
- •Subjects who work in medical institution
- •Household contacts with women who are pregnant or breast-feeding
- •Female subjects who are pregnant or breast-feeding and have positive result by serum pregnancy test or urine pregnancy test, or do not using approved contraceptives such as sterilization, contraceptive ring injectable, combined oral contraceptive pills and barrier contraceptive, combined hormone-based therapy, contraceptive cream, contraceptive jelly, diaphragm or condoms
- •Subjects household member < 1 year old or work with children < 1 year old
- •Subjects with a known history of Cardiac disease or have three or more of the following risk factors: hyperpiesia, obesity, hyperlipidemia, glucosuria, sclerosis, cerebral arteriosclerosis
- •Receipt of immunoglobulin or vaccine within 4 weeks of vaccination
- •Subjects who are allergic to latex, inflammatory opthalmic disease, or taking antiviral agents.
- •Receipt of investigational research agents within 4 months of vaccination
- •HBsAg seropositive
- •HCV antibody seropositive
- •HIV seropositive
- •Subjects having fever (oral temperature > 38℃) or severe nutrition disorder
- •Blood donation within 3 months since screening visit
- •Subject who are not suitable to participate in study according to investigator's judgement
研究组 & 干预措施
Vaccinia-naive group
Experimental
2.5 * 10^5 pfu/dose
干预措施: smallpox vaccine CJ-50300 (Drug)
结局指标
主要结局
Pocket formation
时间窗: 7-9 day
Adverse reactions
时间窗: 0-28 days
次要结局
- Antibody response(14 or 28 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Safety and Efficacy of CJ Smallpox Vaccine in Previously Vaccinated Healthy VolunteersSmallpoxNCT01317238Seoul National University Hospital145
已完成
2 期
Safety and Efficacy of CJ-50300 in Healthy VolunteersSmallpoxNCT00607243Seoul National University Hospital123
已完成
1 期
Safety and Immunogenicity of CJ-50300SmallpoxNCT00336635Seoul National University Hospital24
已完成
2 期
A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic DermatitisAtopic DermatitisNCT00316602Bavarian Nordic632
进行中（未招募）
1 期
Take evaluation and safety of smallpox vaccine (LISTER strain) in naïve healthy adultsVaccination of vaccinia-naive healthy adults (18-25 years old)EUCTR2005-002175-32-FRSanofi Pasteur SA260